Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Cohen

Cardiovascular Disease West Hills, CA Medical Doctor

NPI 1114991767 CMS profile 141198

23101 Sherman Pl, Suite 110, West Hills, CA 91307

Open in the dashboard

General payments

$8,876

401 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Cohen of West Hills, CA is reported in the CMS Open Payments database as having received $8,876 across 401 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $802 16
2024 General $905 62
2023 General $2,059 85
2022 General $1,904 96
2021 General $1,558 64
2020 General $464 19
2019 General $1,185 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Cohen
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Benjamin Cohen were reported at $802. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Benjamin Cohen Cardiovascular Disease median Middle half National median
2019 $1,185 $450 $127–$1,392 $163
2020 $464 $242 $77–$751 $114
2021 $1,558 $335 $101–$1,037 $132
2022 $1,904 $395 $121–$1,211 $149
2023 $2,059 $443 $136–$1,283 $160
2024 $905 $450 $136–$1,323 $164
2025 $802 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,168 75 payments
  2. HeartFlow, Inc. $714 26 payments
  3. Medtronic, Inc. $649 15 payments
  4. Boston Scientific Corporation $600 19 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $546 23 payments
  6. E.R. Squibb & Sons, L.L.C. $493 41 payments
  7. Amgen Inc. $457 22 payments
  8. Medtronic Vascular, Inc. $432 10 payments
  9. Abbott Laboratories $429 17 payments
  10. Pfizer Inc. $389 28 payments
  11. Other $3,001 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,818 399 payments
  2. Debt forgiveness $48 1 payment
  3. Education $11 1 payment
Products named General payments · program years 2019–2025
  1. ENTRESTO $897 60 payments
  2. FFRct $714 26 payments
  3. LifeVest $546 23 payments
  4. Repatha $457 22 payments
  5. XARELTO $381 18 payments
  6. VERQUVO $378 17 payments
  7. ELIQUIS $337 27 payments
  8. VYNDAQEL $333 25 payments
  9. CoreValve Evolut $310 5 payments
  10. LEQVIO $263 16 payments
  11. Other $5,090 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

3,506

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$764,656

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

25.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 218 $243,717
Xarelto Rivaroxaban Brand 63 $95,609
Entresto Sacubitril/Valsartan Brand 75 $94,867
Repatha Sureclick Evolocumab Brand 50 $59,837
Jardiance Empagliflozin Brand 53 $58,188
Farxiga Dapagliflozin Propanediol Brand 39 $45,805
Vascepa Icosapent Ethyl Brand 43 $26,923
Nexlizet Bempedoic Acid/Ezetimibe Brand 23 $14,339
Praluent Pen Alirocumab Brand 16 $12,508
Nexletol Bempedoic Acid Brand 21 $11,888

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$226,130

Of which drugs: $2,574

Medicare patients

672

Average age 77

Services billed

23,490

315 women, 357 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 67%
Arthritis 57%
Diabetes 40%
Atrial fibrillation 34%
Heart failure 27%
Chronic kidney disease 26%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 279 21,767 $2,351

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $125
$125 — —
Repatha
  • Amgen Inc. $94
$94 50 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $94
$94 218 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $56
$56 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $32
$32 63 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

401 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record